AUS
NZ
UK
CA
USA
IND
_06_19_2026_10_41_46_758506.jpg)
Highlights:
-
Sigma Healthcare's share price surged 31% following the approval of its merger with Chemist Warehouse.
-
The Australian Competition & Consumer Commission (ACCC) cleared the merger with specific conditions, including a court-enforceable undertaking.
-
The merger is seen as a strategic move to create a stronger ASX-listed healthcare company, combining Sigma's distribution infrastructure with Chemist Warehouse's retail capabilities.
The proposed merger between Sigma Healthcare Ltd (ASX:SIG) and Chemist Warehouse has been granted approval by the Australian Competition & Consumer Commission (ACCC), resulting in a 31% increase in Sigma's share price. The ACCC's decision followed an extensive review of the merger's potential impact on market competition. The commission concluded that, with specific undertakings in place, the merger is "unlikely to substantially lessen competition" in the pharmaceutical supply chain.
The ACCC’s approval was contingent on Sigma agreeing to a court-enforceable undertaking, which includes a commitment to maintaining effective competition at all levels of the pharmacy supply chain. The regulator emphasized that alternative wholesalers, such as EBOS Group and Wesfarmers' Australian Pharmaceutical Industries, will continue to supply pharmacies, ensuring that retail pharmacies can still access products without facing significant barriers.
Furthermore, Sigma has pledged not to impose restrictive exit clauses on retail pharmacies, allowing them the freedom to switch suppliers without incurring prohibitive costs. Sigma will also safeguard and delete the data of pharmacies that decide to switch, in line with the enforceable undertaking. Additionally, the merged entity will be required to continue operating under the Commonwealth Government's Community Service Obligation (CSO) for a period of five years.
Sigma's management, led by CEO Vikesh Ramsunder, expressed confidence that the merger would create a stronger and more competitive business, combining Sigma's pharmaceutical distribution expertise with Chemist Warehouse's retail know-how. This strategic merger is expected to accelerate Sigma’s long-term growth, benefiting stakeholders and enhancing its position in the healthcare sector.
With the regulatory process nearing completion, Sigma is preparing to send the necessary documentation to shareholders for approval. Once completed, the merger will mark a significant step in creating a leading healthcare company on the ASX, with Chemist Warehouse poised to become an even more prominent player in the sector.
